Nonspecific Interstitial Pneumonitis


Article Author:
Ali Nayfeh


Article Editor:
Douglas Moore


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Abbey Smiley
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
3/2/2019 5:54:32 PM

Introduction

Nonspecific interstitial pneumonia (NSIP) is one class of idiopathic interstitial pneumonia (IIP). NSIP is chronic interstitial pneumonia with the homogeneous appearance of interstitial fibrosis and inflammation. It is nonspecific as it lacks the histopathological features of the other subtypes of the IIP. NSIP typically has bilateral lung involvement and may have a predisposition for the lower lobes.[1][2][3][4][5]

Etiology

Nonspecific interstitial pneumonia can be idiopathic or associated with connective tissue disease, HIV infection, toxins, or numerous other causes. Secondary causes of nonspecific interstitial pneumonia NSIP include:

  1. Connective tissue disease (CTD): NSIP is a common pattern due to underlying connective tissue disease which includes systemic sclerosis, polymyositis/dermatomyositis, rheumatoid arthritis, and Sjogren syndrome.
  2. Drug-induced: Amiodarone, methotrexate, nitrofurantoin, chemotherapeutic agents, and statin therapy have been associated with an NSIP pattern.
  3. HIV infection: Less common now after the widespread use of the antiretroviral therapy. 
  4. Interstitial pneumonia with autoimmune features: those patients have NSIP on lung biopsy, and features of autoimmune disease that don’t match specific connective tissue disease.
  5. Hypersensitivity pneumonitis: In some patients, the lung biopsy lacks granuloma, and multinucleated giant cells through the histopathology have an appearance of NSIP.
  6. Others: Such as an IgG4-related systemic disease, familial interstitial pneumonia, and graft versus host disease

Epidemiology

NSIP is rare. It constitutes 14% to 36% of cases of idiopathic interstitial pneumonia which is less common than usual interstitial pneumonia (UIP) (50% to 60%) but more common than desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease (DIP/RB-ILD) (10-17%) and acute interstitial pneumonia (AIP) (0% to 2%). Idiopathic NSIP occurs mostly in middle-aged women who are non-smokers, while NSIP due to connective tissue disease is equal in men and women.

Pathophysiology

Pathophysiology of the NSIP includes epithelial injury, dysregulated repair, involvement of the immune system based in the presence of lymphocyte in the alveolar septae and bronchoalveolar lavage, and abnormal fibroblast/myofibroblast function leading to excess collagen deposition.[6][7][8]

Histopathology

For the diagnosis of diffuse interstitial lung disease, surgical biopsy via VATS or thoracotomy is the gold standard. Transbronchial cryobiopsy can be used as well. Traditional transbronchial forceps lung biopsies have been reported to have a low diagnostic yield. Ideally, biopsy samples should be obtained from more than one lobeNSIP is a diagnosis of exclusion. Nonspecific gross findings may be observed on wedge biopsy, including increased stiffness of the pulmonary parenchyma secondary to interstitial inflammation and fibrosis. The histopathology of NSIP is characterized by a temporally homogeneous inflammatory and fibrosing interstitial process. Fibroblastic foci and peripheral accentuation are typically absent, which helps to differentiate it from usual interstitial pneumonia (UIP). NSIP is also characterized by diffuse alveolar wall thickening by uniform fibrosis, but with the preservation of the alveolar architecture. Three separate groups within NSIP have been described:

  1. Group 1: Mainly interstitial inflammation 
  2. Group 2: Inflammation and fibrosis 
  3. Group 3: Mainly fibrosis

History and Physical

History

  • The most common symptoms are dyspnea and cough that are progressive over weeks to months 
  • Fever
  • Weight loss 
  • Flu-like symptoms 
  • If CTD is present, the patient may have dry mouth, dry eyes, arthralgias, joint swelling, myalgias, dysphagia, skin changes, or other features

Physical Exam

  • Fine crackles, especially at the bases, may be noted 
  • Clubbing is present in 10% to 35%, though this may be a non-specific finding
  • Exam features of rheumatological disease such as skin changes, joint swelling may also be noted

Evaluation

The evaluation of the patients with possible NSIP include: 

  1. Clinical evaluation: Detailed history and physical exam are important. Patients should be asked about exposure to airborne antigens, medication list, history of exposure to radiation, HIV risk factors, CTD symptoms, as well as family history.
  2. Laboratory test: If CTD is suspected, one should perform an appropriate serological evaluation. One may also consider HIV testing if there are risk factors. 
  3. Pulmonary function testing (PFT): Includes spirometry to determine whether the symptoms are associated with an obstructive or restrictive pattern, lung volumes, diffusing capacity for carbon monoxide (DLCO) to check for gas exchange, and 6-minute walk test to check for hypoxia at rest or exertional hypoxia. Monitoring forced vital capacity (FVC) and DLCO is helpful to monitor for progression and correlate with clinical symptoms as well as to monitor response to treatment and offer additional information on prognosis. Patients with NSIP typically have a spirometric restrictive pattern on the PFTs with reduced TLC and DLCO.
  4.  Imaging: (1) Chest x-ray may show increased basilar markings and/or interstitial prominence bilaterally; (2) High-resolution Computed Tomography (HRCT) of the chest is the gold standard for imaging diagnosis. Most common findings may include increased reticular markings, traction bronchiectasis, volume loss, and ground glass opacification mainly in the lower zones. Honeycomb changes are more common with UIP and usually absent in NSIP. 
  5. Lung biopsy may assist in definitive diagnosis, though may not always be needed. The need for biopsy must be evaluated within the clinical context, including whether there is an identified underlying process or not, and the severity of lung injury. For example, in the case of an associated CTD or drug-induced NSIP, a biopsy may not be needed. Conversely, in those cases where an associated etiology is not discovered, a lung biopsy may be needed for diagnosis.

Treatment / Management

Treatment of NSIP depends on the cause and the severity of the disease:

  • Mild disease: These patients usually have mild symptoms and minimal impairment on their pulmonary functions tests. Close follow up and observation for evidence of disease progression may be adequate.
  • Moderate to severe disease: These patients have moderate to severe symptoms, with significant impairment on their pulmonary function tests as well as diffuse changes on HRCT chest scan. In this scenario, we typically start with systemic steroid therapy (prednisone) at a dose of 0.5 to 1 mg/kg ideal body weight (IBW) up to a maximum dose of 60 mg per day for 1 month, followed thereafter by a dose of 30 to 40 mg per day for an additional 2 months. For those who respond/stabilize with this treatment, the prednisone should be gradually tapered over 6 to 9 months to a dose of 5 to 10 mg per day or every other day with a goal of potential cessation in therapy after 1 year. Typically, patients are monitored on prednisone for 3 to 6 months to assess for response to treatment and tolerance prior to consideration for a second immunosuppressive agent like azathioprine or mycophenolate. However, for patients with a more severe initial disease, clinicians may start systemic steroid therapy along with a second immunosuppression agent together.
  • More severe disease may require hospitalization: These patients may require pulse methylprednisolone at a dose of 1000 mg per day for 3 days, followed by systemic prednisone therapy as outlined above. Rarely is an additional pulse therapy needed.
  • Refractory disease despite systemic steroid and immunosuppressive agents: Consideration may be given for cyclophosphamide, rituximab, or calcineurin inhibitors. Those that are not responsive may be considered for lung transplantation.
  • It is important to be mindful of potential adverse effects to steroid therapy and continue to assess the risks and benefits of steroid therapy. Further, consideration should be given to Pneumocystis jirovecii pneumonia (PJP) prophylaxis in those patients on greater than 20 mg prednisone daily for more than 1 month, or those on multiple immunosuppressive agents, as this infection may significantly worsen lung function.[9]

 Treatment of the secondary causes:

  • Drug induced: Removal from the exposure may be sufficient.  
  • Connective tissue disease: Treatment is focused on the underlying cause. Coordination with a rheumatology specialist may be helpful as well.
  • HIV infection: Exclude infections and then start antiretroviral therapy. Systemic steroids can be used for those who fail to improve.

Differential Diagnosis

  1.  Other idiopathic interstitial pneumonia: The histopathology of usual interstitial pneumonia (UIP) can be seen in both idiopathic pulmonary fibrosis (IPF) as well as NSIP.  Given the potential for clinical and histopathological overlap between these two entities, differentiating the two may be challenging. Fibrotic NSIP should be distinguished from IPF as it has a better prognosis and possible response to steroid therapy.
  2. Hypersensitivity pneumonitis: Typical imaging features in the acute or subacute phase include findings of centrilobular nodules as well as the predominance of upper lung zone involvement. On histopathology, there is the bronchiolocentric distribution of giant cells and poorly formed granulomas. Chronic hypersensitivity pneumonitis may have more fibrotic features, and thus an attempt should be made to discern this disease state by clinical history and potential further evaluation.
  3. IgG-related systemic disease: Some patients with IgG4 have interstitial lung disease. Histopathology may demonstrate infiltration of the lung interstitium with IgG4-positive plasma cells, which helps to differentiate this entity.

Prognosis

The prognosis of NSIP is significantly better than that of UIP. Five and 10-year survival is 43% and 15% respectively among patients with UIP, compared to 86% to 92% 5-year survival and 26% to 40% 10-year survival rates among patients with NSIP with the fibrotic component. Fibrotic NSIP is thought to have a worse prognosis than inflammatory, cellular NSIP.

Enhancing Healthcare Team Outcomes

The diagnosis and management of NSIP is complex and usually requires a team approach that consists of a pathologist, thoracic surgeon, pulmonologist, radiologist, nurse practitioner and an internist. Once the diagnosis is made, the usually treatment for mild disease is observation. Moderate to severe disease usually requires steroids and other potent immunosuppresive agents. These patients need life long follow up as the disease course is marked by relapses and remissions. The prognosis for mild disease is good but for severe disease the life expectancy is significantly reduced. (Level V)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Nonspecific Interstitial Pneumonitis - Questions

Take a quiz of the questions on this article.

Take Quiz
Nonspecific interstitial pneumonitis (NSP):



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 32-year-old woman is evaluated for exertional dyspnea. Medical history is significant for systemic sclerosis. Pulmonary examination reveals bilateral fine basal crackles. Pulmonary function test showed a restrictive pattern with reduced DLCO. CT of the chest showed increased reticular markings, and ground glass opacification mainly in the lower zones with no honeycombing changes. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which one of the following regarding nonspecific interstitial pneumonitis (NSIP) is false?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 42-year-old woman is evaluated for exertional dyspnea and fatigue. Her symptoms began four months ago and have been steadily worsening. Medical history is significant for essential hypertension. She takes amlodipine. On physical examination, vitals are stable, oxygen saturation breathing ambient air is 91%. Pulmonary examination reveals bilateral fine basal crackles. Pulmonary function test showed reduced DLCO. CT chest showed increased reticular markings, traction bronchiectasis, volume loss, and ground glass opacification mainly in the lower zones with no honeycombing changes. Lung biopsy confirmed the diagnosis of nonspecific interstitial pneumonitis (NSIP). What is the best treatment?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Nonspecific Interstitial Pneumonitis - References

References

Hochhegger B,Marchiori E,Zanon M,Rubin AS,Fragomeni R,Altmayer S,Carvalho CRR,Baldi BG, Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics. Clinics (Sao Paulo, Brazil). 2019 Feb 4;     [PubMed]
Abdelghani R,Thakore S,Kaphle U,Lasky JA,Kheir F, Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy. Journal of bronchology     [PubMed]
Wu EK,Ambrosini RD,Kottmann RM,Ritchlin CT,Schwarz EM,Rahimi H, Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. Current rheumatology reviews. 2019 Jan 15;     [PubMed]
Sambataro G,Sambataro D,Pignataro F,Torrisi SE,Vancheri A,Pavone M,Palmucci S,Del Papa N,Vancheri C, Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. Respiratory medicine case reports. 2019;     [PubMed]
Cottin V,Hirani NA,Hotchkin DL,Nambiar AM,Ogura T,Otaola M,Skowasch D,Park JS,Poonyagariyagorn HK,Wuyts W,Wells AU, Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European respiratory review : an official journal of the European Respiratory Society. 2018 Dec 31;     [PubMed]
Richeldi L,Varone F,Bergna M,de Andrade J,Falk J,Hallowell R,Jouneau S,Kondoh Y,Morrow L,Randerath W,Strek M,Tabaj G, Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European respiratory review : an official journal of the European Respiratory Society. 2018 Dec 31;     [PubMed]
Jain A,Shannon VR,Sheshadri A, Immune-Related Adverse Events: Pneumonitis. Advances in experimental medicine and biology. 2018;     [PubMed]
Jakubczyc A,Neurohr C, [Diagnosis and Treatment of Interstitial Lung Diseases]. Deutsche medizinische Wochenschrift (1946). 2018 Dec;     [PubMed]
Greenberger PA, Hypersensitivity pneumonitis: A fibrosing alveolitis produced by inhalation of diverse antigens. The Journal of allergy and clinical immunology. 2018 Nov 15;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.